| Name | Title | Contact Details |
|---|
Instil Bio is a cell therapy company developing tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers. TIL are a patient`s own T cells harvested from the patient`s tumor, which are then expanded and reinfused into the patient to target and kill cancer cells.
NexImmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary AIM™ technology.
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
MaxCyte is a US-based global company dedicated to accelerating the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines.
Tropical Looks Day Spa is a Vacaville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.